Sparsentan

Contraindicated

Sparsentan Aliskiren Tekturna An increased aliskiren exposure and an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (includ... Details Sparsentan Ambrisentan Letairis An increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) Details Sparsentan Azilsartan Edarbi An increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) Details Sparsentan Eprosartan Teveten® An increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) Details Sparsentan Irbesartan Avapro An increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure), reduced CY... Details Sparsentan Losartan Arbli An increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure), reduced CY... Details Sparsentan Macitentan Opsumit An increased risk of hypotension, syncope, hyperkalemia, and changes in renal function, reduced macitentan exposure and reduced ef... Details

Major

Sparsentan Omeprazole Gastrobim Explained Reduced sparsentan exposure, reduced efficacy of sparsentan, reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 su... Details Sparsentan Dexlansoprazole Dexilant Reduced sparsentan exposure, reduced efficacy of sparsentan, reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 su... Details Sparsentan Diclofenac Ophthalmic Voltaren® Eye Drops An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Diclofenac Topical (Actinic Keratosis) Pennsaid An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Diclofenac Topical (Arthritis Pain) Pennsaid® An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Diclofenac Transdermal Patch Flector An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Encorafenib Braftovi Reduced sparsentan exposure and reduced efficacy of sparsentan Details Sparsentan Esomeprazole Nexium Reduced sparsentan exposure, reduced efficacy of sparsentan, reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 su... Details Sparsentan Esomeprazole Injection Nexium Reduced sparsentan exposure, reduced efficacy of sparsentan, reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 su... Details Sparsentan Famotidine Calmicid Reduced sparsentan exposure and reduced efficacy of sparsentan Details Sparsentan Famotidine Injection Calmicid Reduced sparsentan exposure and reduced efficacy of sparsentan Details Sparsentan Flurbiprofen Ansaid An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Flurbiprofen Ophthalmic Ocufen An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Ibuprofen Addaprin An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Ketoconazole Topical Extina® Foam Increased sparsentan exposure and increase the risk of sparsentan-related adverse reactions Details Sparsentan Lansoprazole Prevacid Reduced sparsentan exposure, reduced efficacy of sparsentan, reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 su... Details Sparsentan Lefamulin Xenleta Increased sparsentan exposure, an increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effect... Details Sparsentan Letermovir Injection Prevymis Increased sparsentan exposure, an increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effect... Details Sparsentan Meloxicam Alloxate An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Meloxicam Injection Alloxate An increased risk of kidney injury, reduced CYP2C9 substrate exposure and reduced CYP2C9 substrate efficacy Details Sparsentan Nizatidine Axid® Reduced sparsentan exposure and reduced efficacy of sparsentan Details

Moderate

Sparsentan Sertraline Explained Reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 substrate Details Sparsentan Relugolix Orgovyx Explained Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Sparsentan Colchicine Colcrys Explained Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Sparsentan Abrocitinib Cibinqo Explained Reduced CYP2C19/CYP2C9 substrate exposure and reduced efficacy of CYP2C19/CYP2C9 substrate Details Sparsentan Apixaban Eliquis Explained Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Sparsentan Aspirin Acuprin® An increased risk of worsening of renal function Details Sparsentan Aspirin Rectal Aspirin An increased risk of worsening of renal function Details Sparsentan Avatrombopag Doptelet Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate Details Sparsentan Betrixaban Bevyxxa® Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Sparsentan Afatinib Gilotrif Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Sparsentan Aficamten Reduced CYP2C19/CYP2C9 substrate exposure and reduced efficacy of CYP2C19/CYP2C9 substrate Details Sparsentan Bromfenac Ophthalmic Bromday® An increased risk of worsening of renal function Details